Teva to lose CFO, with turnaround still under construction

Natalie Grover

Reporter

Two years ago, Kåre Schultz took on the gargantuan challenge of fixing a financially troubled, debt-laden Teva with a sparse pipeline. He responded by initiating …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Teva to lose CFO, with turnaround still under construction

Natalie Grover

Reporter

Sign up to read this article for free.

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

FDA approves first drug to treat ultra-rare lipid storage disease

Will CRISPR matter?

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Te­va to lose CFO, with turn­around still un­der con­struc­tion

Natalie Grover

Reporter

Sign up to read this article for free.

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Eli Lil­ly stock­piles $548M of oral weight loss drug ahead of launch

FDA ap­proves first drug to treat ul­tra-rare lipid stor­age dis­ease

Will CRISPR mat­ter?

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

Teva to lose CFO, with turnaround still under construction

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

FDA approves first drug to treat ultra-rare lipid storage disease

Will CRISPR matter?

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence